Patents Assigned to Genentech
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8449883
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: May 28, 2013
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, William Mallet, Paul Polakis
  • Anti-VEGF antibodies
    Patent number: 8449885
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 28, 2013
    Assignee: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
  • Phosphoinositide 3-kinase inhibitor compounds and methods of use
    Patent number: 8450315
    Abstract: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 28, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson, Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130129749
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 23, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130129733
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 23, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
    Publication number: 20130129735
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 23, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20130129820
    Abstract: Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 23, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
    Publication number: 20130129743
    Abstract: The invention provides anti-HtrA1 antibodies and methods of using the same.
    Type: Application
    Filed: October 12, 2012
    Publication date: May 23, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • PURIFICATION OF ANTI-C-MET ANTIBODIES
    Publication number: 20130129718
    Abstract: Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 23, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Purine PI3K inhibitor compounds and methods of use
    Patent number: 8445487
    Abstract: Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 21, 2013
    Assignee: Genentech, Inc.
    Inventors: Georgette Castanedo, Irina Chuckowree, Adrian Folkes, Daniel P. Sutherlin, Nan Chi Wan
  • BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20130123263
    Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 16, 2013
    Applicants: F. HOFFMANN - LA ROCHE AG, GENENTECH, INC.
    Inventors: GENENTECH, INC., F. HOFFMANN - LA ROCHE AG
  • Refolding of Recombinant Proteins
    Publication number: 20130123474
    Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 16, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
    Patent number: 8440402
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: May 14, 2013
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS
    Publication number: 20130116246
    Abstract: 8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • BICYCLIC PIPERAZINE COMPOUNDS
    Publication number: 20130116262
    Abstract: Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ALKYLATED PIPERAZINE COMPOUNDS
    Publication number: 20130116245
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS
    Publication number: 20130116235
    Abstract: Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE
    Publication number: 20130115626
    Abstract: The invention provides anti-NRP1 antibodies and methods of using the same.
    Type: Application
    Filed: January 9, 2013
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • NEUROPILIN ANTAGONISTS
    Publication number: 20130115214
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: January 11, 2013
    Publication date: May 9, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 8436147
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: May 7, 2013
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits